### Pharmacy and Therapeutics Committee Virtual Meeting

**May 19, 2021**  
**12:00pm - 5:00pm**

**Zoom Meeting Registration:** [https://ahcccs.zoom.us/webinar/register/WN_AvFfok-xRwmpKlFRNlyPbw](https://ahcccs.zoom.us/webinar/register/WN_AvFfok-xRwmpKlFRNlyPbw)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
</tr>
</thead>
</table>
| 12:00 PM | Welcome and Introductions: Suzi Berman, RPh, AHCCCS Pharmacy Director  
  - January 26, 2021 - P&T Minutes Review and Vote  
  - All submitted written testimony will be posted on the AHCCCS website under Pharmacy/Pharmacy & Therapeutics Committee  
  - The HIV agenda item from the last meeting will be incorporated into the full review of HIV medications to be presented at the October meeting. |
| 12:15 PM | Conflict of Interest Training: AHCCCS Office of Administrative Legal Services – Susan Russo |
| 1:00 PM  | Supplemental Rebate Class Reviews: Clinical reviews by Hind Douiki, PharmD, Magellan  
  1. Analgesics – Narcotics Long-Acting Agents  
     a. Public Testimony: None  
  2. Antibiotics, Inhaled  
     a. Public Testimony: None  
  3. Anticoagulants  
     a. Public Testimony: None  
  4. Antimigraine Agents - Other  
     a. Public Testimony: None  
  5. Antipsychotic – Oral Atypicals 2\textsuperscript{nd} Generation  
     a. Public Testimony: None  
  6. Antipsychotics – Atypical Long-Acting Injectables  
     a. Public Testimony: None  
  7. COPD Agents  
     a. Public Testimony: None  
  8. Cytokine and CAM Antagonists  
     a. Public Testimony: None  
  9. Epinephrine, Self-Injected  
     a. Public Testimony: None |
10. Glucagon Agents  
   a. Public Testimony: None

11. Glucocorticoids – Inhaled  
   a. Public Testimony: None

12. Growth Hormone  
   a. Public Testimony: None

13. Hepatitis C Agents – Other  
   a. Public Testimony: None

14. Hepatitis C DAA Agents  
   a. Public Testimony: None

15. Hypoglycemics, Incretin Mimetics/Enhancers  
   a. Public Testimony: None

16. Hypoglycemics – Insulin and Related Agents  
   a. Public Testimony: None

17. Opioid Dependence Agents  
   a. Public Testimony: Oral  
      i. Megan Aronson
      ii. Steven Locnikar, DO

18. Pancreatic Enzymes  
   a. Public Testimony: None

19. Progestational Agents  
   a. Public Testimony: None

20. Stimulants and Related Agents  
   a. Public Testimony: None

21. Skin Substitutes  
   a. Public Testimony  
      i. Katie Artz, MD  
      ii. Bashar Majeed, MD

2:30 PM  
**New Drug Reviews:** Hind Douiki, PharmD, Magellan

<table>
<thead>
<tr>
<th>Brand Name</th>
<th>Generic Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Bronchitol</td>
<td>Mannitol</td>
</tr>
<tr>
<td>2. Cabenuva</td>
<td>Cabotegravir/Rilpivirine</td>
</tr>
<tr>
<td>3. Gemtesa</td>
<td>Vibegron</td>
</tr>
<tr>
<td>4. Lupkynis</td>
<td>Vocolosporin</td>
</tr>
<tr>
<td>5. Ponvory</td>
<td>Ponesimod</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
</tr>
<tr>
<td>-----------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>3:00 PM</td>
<td><strong>Break &amp; Executive Session:</strong> Chris Andrews, PharmD, Magellan</td>
</tr>
<tr>
<td>4:30 PM</td>
<td><strong>Public Therapeutic Class Votes:</strong> Hind Douiki, PharmD, Magellan</td>
</tr>
<tr>
<td>5:00 PM</td>
<td><strong>Meeting Adjournment</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Future Meeting Dates:</strong></td>
</tr>
<tr>
<td></td>
<td>October 18, 2021</td>
</tr>
<tr>
<td></td>
<td>January 19, 2022</td>
</tr>
</tbody>
</table>

| 6. Verquvo | Vericiguat |
| 7. Vocabria | Cabotegravir |